SCHEMBL11035375

SCHEMBL11035375

COCCOCCC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
CA2 P00918 1/20 0.36
LMNA P02545 2/20 0.36
SLC15A2 Q16348 1/20 0.36
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
TSHR P16473 4/20 0.34
ABCB11 O95342 1/20 0.32
CYP3A4 P08684 1/20 0.32
ADRA2B P18089 1/20 0.32
OPRD1 P41143 1/20 0.32
SCN5A Q14524 1/20 0.32
CTNNB1 P35222 1/20 0.31
CES2 O00748 1/20 0.31
EPHX2 P34913 2/20 0.31
ACHE P22303 1/20 0.31
PAOX Q6QHF9 1/20 0.31
ASGR1 P07306 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14924286 1.00 ALDH1A1 (0.43) ALDH1A1CA2LMNASLC15A2MGAM
SCHEMBL12081795 1.00 ALDH1A1 (0.43) ALDH1A1CA2LMNASLC15A2MGAM
SCHEMBL15580618 1.00 ALDH1A1 (0.43) ALDH1A1CA2LMNASLC15A2MGAM
SCHEMBL14924285 1.00 ALDH1A1 (0.43) ALDH1A1CA2LMNASLC15A2MGAM
SCHEMBL14134546 1.00 ALDH1A1 (0.43) ALDH1A1CA2LMNASLC15A2MGAM
SCHEMBL16256864 1.00 ALDH1A1 (0.43) ALDH1A1CA2LMNASLC15A2MGAM
SCHEMBL14134613 1.00 ALDH1A1 (0.43) ALDH1A1CA2LMNASLC15A2MGAM
SCHEMBL10086608 0.89 ALDH1A1 (0.53) ALDH1A1LMNASLC15A2MGAMGAA
SCHEMBL18769029 0.89 ALDH1A1 (0.53) ALDH1A1LMNASLC15A2MGAMGAA
SCHEMBL22198371 0.89 ALDH1A1 (0.53) ALDH1A1LMNASLC15A2MGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-59078139-A None JP disclosed
US-20230346969-A1 INTERMEDIATE FOR PREPARING ANTIBODY-DRUG CONJUGATE (ADC), PREPARATION METHOD THEREFOR, AND USE THEREOF DARTSBIO PHARMACEUTICALS LTD. (CN) 2023-11-02 US disclosed
US-11795320-B2 Grafted polymer and use thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2023-10-24 US disclosed
US-20180170812-A1 METAL OXIDE CERAMIC NANOMATERIALS AND METHODS OF MAKING AND USING SAME IVOCLAR VIVADENT AG (LI) 2018-06-21 US disclosed
US-20180134717-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF SPIROGEN LIMITED (GB) 2018-05-17 US disclosed
WO-2017205309-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-30 WO disclosed
WO-2017205191-A1 INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES MERCK SHARP & DOHME CORP. (US) 2017-11-30 WO disclosed
US-9820917-B1 Metal oxide ceramic nanomaterials and methods of making and using same IVOCLAR VIVADENT AG (LI) 2017-11-21 US disclosed
US-9822039-B1 Metal oxide ceramic nanomaterials and methods of making and using same IVOCLAR VIVADENT AG (LI) 2017-11-21 US disclosed
US-9801944-B2 Lipocationic polymers and uses thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-10-31 US disclosed
US-9517270-B2 Lipocationic polymers and uses thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-12-13 US disclosed
US-20160310612-A1 PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS SEATTLE GENETICS, INC. (US) 2016-10-27 US disclosed
US-20160220681-A1 LIPOCATIONIC POLYMERS AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-08-04 US disclosed
US-20160220681-A1 LIPOCATIONIC POLYMERS AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-08-04 US disclosed
US-9394227-B1 Treprostinil derivatives and compositions and uses thereof Corsair Pharma, Inc. (US) 2016-07-19 US disclosed
WO-2016081670-A2 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-05-26 WO disclosed
US-20140142044-A1 PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) 2014-05-22 US disclosed
US-20070172422-A1 Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications GLAZIER ARNOLD 2007-07-26 US disclosed
US-20070154992-A1 Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants NEOSE TECHNOLOGIES, INC. (US) 2007-07-05 US disclosed
JP-S5978139-A NOVEL KETO ETHER COMPOUND AND PREPARATION THEREOF CHISSO CORP 1984-05-04 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142044-A1 PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE PLK1, PLK4, PLK3 ALDH1A1 4542/4885CA2 4262/4885LMNA 2211/4885
US-20230346969-A1 INTERMEDIATE FOR PREPARING ANTIBODY-DRUG CONJUGATE (ADC), PREPARATION METHOD THEREFOR, AND USE THEREOF WEE1, THEM6, KIF11 ALDH1A1 546/4885CA2 4566/4885LMNA 2954/4885
US-20070172422-A1 Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications EPHA2, EEA1, HAVCR2 ALDH1A1 4187/4885CA2 2945/4885LMNA 4082/4885
US-20180134717-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF HDAC10, PBDC1, PDCD10 ALDH1A1 1192/4885CA2 4752/4885LMNA 2456/4885
US-20160220681-A1 LIPOCATIONIC POLYMERS AND USES THEREOF NSUN3, METTL16, TRDMT1 ALDH1A1 2579/4885CA2 4638/4885LMNA 156/4885
US-20160310612-A1 PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS EGFR, HDGF, CD47 ALDH1A1 1001/4885CA2 4616/4885LMNA 155/4885
US-20070154992-A1 Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants GHITM, PTMS, GHRHR ALDH1A1 4799/4885CA2 3991/4885LMNA 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.